| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7744582 | OTTER PHARMS | Needle assisted jet injector |
Aug, 2019
(4 years ago) | |
| USRE44847 | OTTER PHARMS | Needle assisted jet injector |
Aug, 2019
(4 years ago) | |
| USRE44846 | OTTER PHARMS | Needle assisted jet injector |
Aug, 2019
(4 years ago) | |
| US7776015 | OTTER PHARMS | Needle assisted jet injector |
Aug, 2019
(4 years ago) | |
| US6746429 | OTTER PHARMS | Needle assisted jet injector |
Apr, 2020
(4 years ago) | |
| US9533102 | OTTER PHARMS | Prefilled syringe jet injector |
Jan, 2026
(1 year, 9 months from now) | |
| US9629959 | OTTER PHARMS | Prefilled syringe jet injector |
Jan, 2026
(1 year, 9 months from now) | |
| US11446441 | OTTER PHARMS | Prefilled syringe injector |
Jan, 2026
(1 year, 9 months from now) | |
| US8562564 | OTTER PHARMS | Prefilled syringe jet injector |
Jan, 2026
(1 year, 9 months from now) | |
| US8021335 | OTTER PHARMS | Prefilled syringe jet injector |
Oct, 2026
(2 years from now) | |
| US10709844 | OTTER PHARMS | Injector safety device |
Mar, 2029
(4 years from now) | |
| US9867949 | OTTER PHARMS | Injector safety device |
Mar, 2029
(4 years from now) | |
| US11684723 | OTTER PHARMS | Injector safety device |
Mar, 2029
(4 years from now) | |
| US8945063 | OTTER PHARMS | Hazardous agent injection system |
Mar, 2030
(5 years from now) | |
| US9421333 | OTTER PHARMS | Hazardous agent injection system |
Mar, 2030
(5 years from now) | |
| US8480631 | OTTER PHARMS | Hazardous agent injection system |
Mar, 2030
(5 years from now) | |
| US11497753 | OTTER PHARMS | Hazardous agent injection system |
Mar, 2030
(5 years from now) | |
| US8579865 | OTTER PHARMS | Hazardous agent injection system |
Mar, 2030
(5 years from now) | |
| US8814834 | OTTER PHARMS | Injector safety device |
May, 2031
(7 years from now) | |
Otrexup is owned by Otter Pharms.
Otrexup contains Methotrexate.
Otrexup has a total of 19 drug patents out of which 5 drug patents have expired.
Expired drug patents of Otrexup are:
- US7744582
- USRE44847
- USRE44846
- US7776015
- US6746429
Otrexup was authorised for market use on 07 November, 2014.
Otrexup is available in solution;subcutaneous dosage forms.
Otrexup can be used as subcutaneous injection of methotrexate.
The generics of Otrexup are possible to be released after 27 May, 2031.
Drugs and Companies using METHOTREXATE ingredient
Market Authorisation Date: 07 November, 2014
Treatment: Subcutaneous injection of methotrexate
Dosage: SOLUTION;SUBCUTANEOUS
OTREXUP family patents
